Press Releases for LCI

Press Releases
Lannett Reauthorizes Stock Repurchase Program
Lannett Reports Fiscal 2010 First-Quarter Financial Results
Lannett Company Files Universal Shelf Registration Statement on Form S-3
Lannett Reports Fiscal 2009 Fourth-Quarter, Full-Year Financial Results
Lannett Company to Report Fiscal 2009 Fourth-Quarter, Full-Year Financial Results and Host Conference Call on Wednesday, September 9, 2009
Lannett Company Announces Positive FDA Inspection Results
Lannett Company Announces William Farber Resumes Role as Chairman
Lannett Company to Be Added to Russell 2000 Index
Lannett Company Names Terence D. Vollrath Executive Vice President
Lannett Reports Fiscal 2009 Third Quarter Financial Results
Lannett Company Receives FDA Approval for Pilocarpine HCI Tablets 7.5 mg Strength
Lannett Company to Report Fiscal 2009 Third-Quarter Financial Results and Host Conference Call on Tuesday, May 12, 2009
Lannett Company Provides Update on Marketing Digoxin Tablets - Apr 2 2009 1:03PM
Lannett Company Comments on FDA Action
Lannett Company Announces Chief Financial Officer Resignation
Lannett to Present at Roth 21st Annual Orange County Growth Stock Conference
Lannett Reports Fiscal 2009 Second Quarter Financial Results
Lannett Company to Report Fiscal 2009 Second-Quarter Financial Results and Host Conference Call on Wednesday, February 11, 2009
Lannett Company Receives FDA Approval for Ursodiol 300 mg Capsules
Lannett Announces Launch of Two Products
Lannett Reports Strong Fiscal 2009 First-Quarter Financial Results
Lannett Company to Report Fiscal 2009 First-Quarter Financial Results and Host Conference Call on Thursday, November 13, 2008
Lannett Receives Patent Approval for Method of Manufacturing Certain Morphine Derivatives
Lannett Announces Positive Results of Facilities Inspection
Lannett Reports Fiscal 2008 Fourth Quarter, Full-Year Financial Results
Lannett Company Announces William Farber, Chairman of the Board, Takes Medical Leave
Lannett Announces Immediate Availability of Bulk Packs
Lannett Company Receives FDA Approvals for Doxycycline Tablets, 75 mg and 150 mg
Lannett Company Granted Import License from DEA
Lannett Company Comments on Litigation with KV Pharmaceuticals
Lannett Company to Launch Amantadine Hydrochloride Soft Gel Capsules, 100 mg
Lannett Reports Fiscal 2008 Third-Quarter Financial Results - May 27 2008 12:54AM
Lannett Company Provides Update on Marketing Digoxin Tablets - May 27 2008 12:54AM
Lannett Chairman Transfers Five Million Shares of Stock - May 27 2008 1:39AM
Lannett Company to Remain a Major Marketer of Digoxin Tablets
Lannett Company Receives Approval for Dipyridamole Tablets USP, 25 mg, 50 mg, and 75 mg